Together, our results strongly suggest that therapeutic strategies targeted to ASMase-mediated activation might be beneficial in attenuating oxidative stress, apoptosis and cardiomyopathy associated with obesity, type 2 diabetes, and insulin resistance. Here, SMPD1 is linked to obesity due to melanocortin 4 receptor deficiency.